surpass-cvot tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular Outcomes in Type 2 Diabetes Tirzepatide vs Dulaglutide for Cardiovascular

Retatrutide is being studied as a multi-receptor therapy

Researchers investigate whether GCGR co-activation in a triple-agonist context contributes to hepatic fat reduction and energy expenditure beyond what GLP-1R and GIPR agonism alone produce

GIP also enhances insulin secretion and may have additional effects on metabolism, though the precise mechanisms contributing to weight loss are not fully understood

Unlike regular diets that you might try on your own, these programs offer personalized plans, often including medications and expert advice to help you lose weight safely and keep it off for good

doi: 10.2337/db08-0349 26